Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3‐dependent mechanism in vitro and in vivo

Lin Li,Xiaoyan Hu,Jewel Nkwocha,Maciej Kmieciak,Mark B. Meads,Kenneth H. Shain,Raghunandan R. Alugubelli,Ariosto S. Silva,Hashim Mann,Praneeth R. Sudalagunta,Rafael R. Canevarolo,Liang Zhou,Steven Grant

DOI: https://doi.org/10.1111/bjh.19796

2024-10-10

British Journal of Haematology

Abstract:ATR antagonists, by preventing Tyr705 phosphorylation of the STAT3 TAD, may disrupt STAT3 dimerization and nuclear transport. The resulting STAT3 inactivation is amplified by MEK1/2 inhibitors, which target the STAT3 TAD at Ser727 residues, required for optimal DNA binding and transactivation. The net effect of combined ATR/MEK1/2 inhibition is dual dephosphorylation of STAT3, and more pronounced downregulation of its targets BCL‐XL and c‐MYC, implicated in MM cell proliferation and survival. Summary Mechanisms underlying potentiation of the anti‐myeloma (MM) activity of ataxia telangiectasia Rad3 (ATR) antagonists by MAPK (Mitogen‐activated protein kinases)‐related extracellular kinase 1/2 (MEK1/2) inhibitors were investigated. Co‐administration of the ATR inhibitor (ATRi) BAY1895344 (BAY) and MEK1/2 inhibitors, for example, cobimetinib, synergistically increased cell death in diverse MM cell lines. Mechanistically, BAY and cobimetinib blocked STAT3 Tyr705 and Ser727 phosphorylation, respectively, and dual dephosphorylation triggered marked STAT3 inactivation and downregulation of STAT3 (Signal transducer and activator of transcription 3) downstream targets (c‐Myc and BCL‐XL). Similar events occurred in highly bortezomib‐resistant (PS‐R) cells, in the presence of patient‐derived conditioned medium, and with alternative ATR (e.g. M1774) and MEK1/2 (trametinib) inhibitors. Notably, constitutively active STAT3 c‐MYC or BCL‐XL ectopic expression significantly protected cells from BAY/cobimetinib. In contrast, transfection of cells with a dominant‐negative form of STAT3 (Y705F) sensitized cells to cobimetinib, as did ATR shRNA knockdown. Conversely, MEK1/2 knockdown markedly increased ATRi sensitivity. The BAY/cobimetinib regimen was also active against primary CD138+ MM cells, but not normal CD34+ cells. Finally, the ATR inhibitor/cobimetinib regimen significantly improved survival in MM xenografts, including bortezomib‐resistant models, with minimal toxicity. Collectively, these findings suggest that combined ATR/MEK1/2 inhibition triggers dual STAT3 Tyr705 and Ser727 dephosphorylation, pronounced downregulation of cytoprotective targets and MM cell death, warranting attention as a novel therapeutic strategy in MM.

hematology